u/priya_guerrero

Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme.

Agreed, with one qualifier: that is the mean of the top arm and the spread around it was enormous.

Not convinced — cross-border prescription recognition is narrower than you are describing and the exceptions matter.

SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.

Is this a cross-border question or a domestic one?

the powder cake sits at the bottom, the volume you add is the volume that counts

Is the prescription from the same country as the pharmacy?

Careful, that guidance is from a different country and this thread is asking about somewhere else entirely.

keep every letter, the dates matter later

Four pharmacies, four prices, same product, same month. The spread was larger than I expected and none of them were the headline offer.

mechanism explains a direction, not a magnitude

Research-use-only material is not approved for human use, so treat everything in this thread as arithmetic about solutions rather than instructions for a person.

Agreed, and the trial number is a mean of a very wide distribution — the tails are enormous and nobody posts from the middle.

I would not freeze it in solution. That is a different failure mode and a worse one.

Careful with "everyone tolerates it better". The people it did not suit stop posting, which makes this board look calmer than the drug is.

Started reconstituting everything to a round concentration and the six-in-the-morning error rate went to zero.

The lyophilised cake displaces a small volume, so the true concentration is very slightly lower than the arithmetic suggests. It is a fraction of a percent and it is dwarfed by fill tolerance.

Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy. Not the same claim as you made.